See the DrugPatentWatch profile for linzess
When Does Linzess Patent Exclusivity End?
Linzess, a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), has patent protection. According to DrugPatentWatch.com, the expected expiry date for its primary patent is in 2028 [1]. However, the exact end of market exclusivity can be influenced by various factors, including potential patent challenges and the granting of additional patents [1].
What Happens When Linzess Patents Expire?
Once the patents protecting Linzess expire, the door opens for generic manufacturers to produce and sell their own versions of the drug. This typically leads to increased competition and a significant reduction in the drug's price [1]. Patients may then have access to more affordable treatment options.
Can Generic Versions of Linzess Be Available Before Patent Expiry?
In some cases, generic versions of a drug can become available before the primary patent expires through legal challenges to those patents. If a patent is invalidated or found to be infringed upon, generic companies might be able to launch their products earlier. Additionally, exclusivities granted by regulatory bodies, such as the FDA, can also affect market entry timelines independently of patent expiry [1].
Who Manufactures Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [2]. Ironwood Pharmaceuticals originally discovered the drug, and AbbVie is responsible for its commercialization.
How Does Linzess Work?
Linzess works by activating guanylate cyclase-C (GC-C) in the intestinal wall. This activation increases intestinal fluid secretion and motility, helping to soften stool and promote bowel movements [3]. This mechanism addresses the underlying issues of constipation.